Federal award (DEFINITIVE CONTRACT, fiscal year 2023)
Recipient: ABVIRO LLC
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2023-09-25 to 2024-06-24
Current total value of award: $2507553
Description: TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1.